NHS criteria and how they are applied in practice — the long version

Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that.

A coverage question with the paperwork detail included, since that is what determines the answer.

Denial received, with a stated reason. My reading of the reason is that it tells me exactly what to submit next, which is the useful thing about a well-written denial.

Before I spend a week on it: is my reading of the stated criterion correct, and is there a documented precedent for this specific ground?

Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.

Picking up post #2: that is the part I would want checked first.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Coming back to the opening post, because the follow-up matters more than the original answer.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

I read post #6 twice before replying, because I had assumed the opposite.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

post #8 answers the question as asked. The question underneath it is different.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

On post #6 — agreed on the reasoning, with one qualification.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

Picking up post #9: that is the part I would want checked first.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.